We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that the European Patent Office (EPO) has granted European Patent No...
SOUTH SAN FRANCISCO, Calif., March 9, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...
SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that it has received notification from The NASDAQ Stock Market that it...
SOUTH SAN FRANCISCO, Calif., March 1, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD), a biopharmaceutical company focused on the development and commercialization of new...
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new...
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) today announced that vosaroxin, the Company's lead drug candidate, has been granted...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions